Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P-pVAC-SARS-CoV-2: Phase I single-center safety and immunogenicity trial of multi-peptide vaccination to prevent COVID-19 infection in adults
2020-002502-75Phase 2Completed
- Sponsor
- University Hospital Tübingen
- Start
- Jun 2020
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CoVac-1 in coronavirus disease 2019 (COVID-19), sponsored by University Hospital Tübingen. Primary endpoint: Incidence of critical events associated with CoVac-1 administration. Started Jun 2020; status: completed.
02
Drugs
CoVac-1
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-002502-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002502-75.